BioAge Labs (NASDAQ:BIOA) Releases Earnings Results, Misses Expectations By $0.05 EPS

BioAge Labs (NASDAQ:BIOA) announced its earnings results on Thursday. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.05), FiscalAI reports. The business had revenue of $0.30 million for the quarter. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%.

BioAge Labs Stock Performance

Shares of BIOA stock traded down $0.42 during trading hours on Thursday, hitting $5.53. 672,199 shares of the company were exchanged, compared to its average volume of 722,497. The stock has a market capitalization of $253.81 million, a price-to-earnings ratio of -2.32 and a beta of 1.19. BioAge Labs has a one year low of $4.81 and a one year high of $25.95. The business’s 50-day simple moving average is $7.17 and its two-hundred day simple moving average is $15.63.

Institutional Trading of BioAge Labs

Several institutional investors and hedge funds have recently bought and sold shares of the company. Profund Advisors LLC increased its stake in BioAge Labs by 601.1% during the third quarter. Profund Advisors LLC now owns 76,284 shares of the company’s stock valued at $541,000 after purchasing an additional 65,404 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of BioAge Labs during the third quarter worth $104,000. Engineers Gate Manager LP acquired a new stake in shares of BioAge Labs during the second quarter worth $344,000. Squarepoint Ops LLC lifted its position in shares of BioAge Labs by 23.3% in the 2nd quarter. Squarepoint Ops LLC now owns 68,436 shares of the company’s stock worth $1,677,000 after buying an additional 12,916 shares during the last quarter. Finally, Corient Private Wealth LP lifted its position in shares of BioAge Labs by 76.7% in the 2nd quarter. Corient Private Wealth LP now owns 40,258 shares of the company’s stock worth $987,000 after buying an additional 17,476 shares during the last quarter.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. UBS Group assumed coverage on BioAge Labs in a report on Sunday, October 11th. They set a “neutral” rating and a $8.00 price objective on the stock. Needham & Company LLC reduced their target price on BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Roth Capital reissued a “buy” rating and set a $25.00 price target on shares of BioAge Labs in a research report on Wednesday, September 9th. Jefferies Financial Group set a $21.00 price target on shares of BioAge Labs in a research report on Friday, July 31st. Finally, Weiss Ratings upgraded shares of BioAge Labs from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, October 26th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $33.00.

BioAge Labs Company Profile

BioAge Labs, Inc is a clinical-stage biotechnology company focused on developing medicines that target the biological mechanisms of aging. The company seeks to address diseases associated with aging by identifying therapeutic targets linked to human longevity and translating those discoveries into drug candidates.

BioAge uses large human data sets, computational biology, and machine-learning tools to study the molecular factors that influence healthy aging and age-related disease. Its research has produced a pipeline of investigational therapies, including azelaprag (BGE-105), an apelin receptor agonist being evaluated for potential applications involving metabolic health, body composition, and physical function.

Founded in 2015, BioAge is headquartered in Richmond, California, and conducts research and clinical development activities through collaborations and studies involving patients and research sites in multiple regions.